ECCO 2018

IBD diagnostics

IBD disease patterns and genetics

Quiescent disease, characteristics and biomarker correlations

Trial

REACT, CALM

Conference

ECCO 2018

28 May, 2018 23:54

ILC1 distribution predicts response to ustekinumab

Conference

ECCO 2018

28 May, 2018 22:58

Central role of IL-23 in molecular resistance to anti-TNF therapy

Conference

ECCO 2018

28 May, 2018 21:06

Genetic predisposition for gut barrier dysfunction

Conference

ECCO 2018

28 May, 2018 20:15

Targeting early disease: lessons from rheumatoid arthritis

Trial

OPTIMA

Conference

ECCO 2018

28 May, 2018 19:27

Targeting early disease: lessons from rheumatoid arthritis

28 May, 2018 19:19

Integration of “omics” and potential for clinical practice

Conference

ECCO 2018

28 May, 2018 18:29

Novel treatment strategies

Combining new drugs with different mechanisms

Trial

EXPLORER

Conference

ECCO 2018

28 May, 2018 23:31

Cobitolimod induces anti-inflammatory effects by balancing Th17/T-reg cell response

Conference

ECCO 2018

28 May, 2018 22:36

Apremilast in active UC shows promising results

Conference

ECCO 2018

28 May, 2018 21:40

Early and significant effects with upadacitinib induction treatment

Trial

CELEST

Conference

ECCO 2018

28 May, 2018 20:45

Vedolizumab induces endoscopic remission and healing in refractory CD

Trial

VERSIFY

Conference

ECCO 2018

28 May, 2018 19:50

SHP647 is efficacious and well-tolerated in CD

Trial

OPERA I, OPERA II, TOSCA

Conference

ECCO 2018

28 May, 2018 18:53

Higher rates of remission and healing with vedolizumab vs. TNF antagonist

Conference

ECCO 2018

28 May, 2018 17:57

Comparative effectiveness of vedolizumab and ustekinumab in CD

Conference

ECCO 2018

28 May, 2018 16:01

Efficacy and safety of biologics

Vedolizumab in anti-TNF-naïve IBD patients and safety profile

Trial

GEMINI

Conference

ECCO 2018

28 May, 2018 23:04

Long-term safety profile of adalimumab

Trial

ULTRA 1, ULTRA 2

Conference

ECCO 2018

28 May, 2018 22:07

Overall manageable safety profile of tofacitinib in long-term use

Conference

ECCO 2018

28 May, 2018 21:10

Oncology in IBD

Long-term risk of advanced neoplasia after colonic low-grade dysplasia in IBD

Conference

ECCO 2018

28 May, 2018 23:13

Cancer risk in IBD associated with age and recent immunomodulator use

Conference

ECCO 2018

28 May, 2018 22:24

Shallow whole-genome sequencing predicts future cancer risk of LGD in UC

Conference

ECCO 2018

28 May, 2018 21:30

Malignancies occur infrequently with tofacitinib

Conference

ECCO 2018

28 May, 2018 20:35

SLC12A2 potential marker of dysplasia associated to inflammation in UC

Conference

ECCO 2018

28 May, 2018 19:40

Significantly increased risk of CRC and/or HGD after appendectomy in UC

Conference

ECCO 2018

28 May, 2018 18:43

Surgery for IBD

Enhanced post-operative recovery pathways for IBD patients

Conference

ECCO 2018

28 May, 2018 23:46

Higher colectomy rate with infliximab vs. conventional therapies in more severe UC

Conference

ECCO 2018

28 May, 2018 22:50

Significant reduction of emergency stoma surgeries for CD

Conference

ECCO 2018

28 May, 2018 21:52